Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

The Trustees of Columbia University in the City of New York C/O Clinical Trials

Neither a doctor nor a teaching hospital

Research payments

$4,401,167

641 payments

Through program year 2025, The Trustees of Columbia University in the City of New York C/O Clinical Trials is reported as receiving $4,401,167 in research payments, across 641 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $1,687,994 123
2024 Research $1,595,301 421
2023 Research $438,392 21
2022 Research $209,026 25
2021 Research $444,533 49
2020 Research $25,921 2

Breakdown

Who paid Research payments · program years 2020–2025
  1. Celgene Corporation $1,750,420 15 payments
  2. Karyopharm Therapeutics Inc. $1,052,526 412 payments
  3. E.R. Squibb & Sons, L.L.C. $785,202 3 payments
  4. Rhythm Pharmaceuticals, Inc. $755,081 197 payments
  5. Exelixis Inc. $57,938 14 payments
Studies the money was for Research payments · program years 2020–2025
  1. A Phase 1/2 Study of Selinexor in Combination with SOC Therapy for Newly Diagnosed or Recurrent Glioblastoma $833,833 386 payments
  2. A Phase 1, Multicenter, Single-arm, Dose-escalation Study Of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants with Autoimmune Neurological Diseases: Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS), or Refractory Myasthenia Gravis (MG) (Breakfree-2) $701,903 1 payment
  3. CD19 SLE Phase I Esc/Exp Study - A Phase 1, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted Nex-T Chimeric Antigen Receptor (CAR) T Cells, in Participants with Severe, Refractory Autoimmune Diseases: Systemic Lupus Erythematosus, Idi $614,541 1 payment
  4. Ph I FIH mCRPC mono CC-94676-PCA-001 - A phase 1, multi-center, open-label, dose finding study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cc-94676 in subjects with metastatic castration-resistant prostate cancer $455,359 2 payments
  5. EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway $259,460 82 payments
  6. A Phase 1, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted Nex-T Chimeric Antigen Receptor (CAR) T Cells, in Participants with Severe, Refractory Autoimmune Diseases: Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, or Rheumatoid Arthritis (Breakfree-1) $225,391 1 payment
  7. A Phase 1, Multi-center, Open-label, Dose Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cc-94676 in Subjects With Metastatic Castration-resistant Prostate Cancer $200,080 1 payment
  8. A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity $192,400 50 payments
  9. DAYBREAK: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway $188,000 52 payments
  10. Experiments in cell lines (No Study No. ID) $97,200 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record